ONTARGET: Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome

Sponsor

Onconova Therapeutics, Inc. (Industry)

Overall Status

Completed

CT.gov ID

NCT01584531

Collaborator

(none)

Enrollment

Locations

Arm

Duration (Months)

16.4

Patients Per Site

0.4

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The primary objectives of this study are to determine if rigosertib sodium, given orally in the form of soft gel capsules, is safe and is associated with a reduction in the number of blood transfusion units that are needed in patients with myelodysplastic syndrome (MDS) classified as Low or Intermediate-1 (Int-1) (any cytogenetics) or trisomy 8 Intermediate 2 (Int-2) in the International Prognostic Scoring System (IPSS) who are transfusion-dependent. Rigosertib will be taken on days 1 to 21 of a 21-day cycle.

Condition or Disease	Intervention/Treatment	Phase
Myelodysplastic Syndrome MDS Trisomy 8	Drug: rigosertib	Phase 2

Detailed Description

This will be a Phase II open-label, multicenter (up to 5 centers), single-arm study. Sixty transfusion-dependent patients with MDS classified as Low or Int-1 risk (any cytogenetics) or trisomy 8 Int-2 by International Prognostic Scoring System (IPSS) will be enrolled to receive rigosertib BID for 21 consecutive days of a 21-day cycle.

Patients will be stratified on prior treatment with azacitidine and/or decitabine and/or lenalidomide and/or erythropoietin.

Patients will remain treated on study until 2006 Internation Working Group (IWG) progression criteria are met or until death from any cause.

All study participants will be allowed, as medically justified, access to RBC and platelet transfusions, and to filgrastim [G-CSF]. Erythropoiesis-stimulating agents (ESAs) will not be allowed during the initial 3 cycles. Rigosertib dosing adjustment policies are described in Protocol.

Study Design

Study Type:

Interventional

Actual Enrollment :

82 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification

Study Start Date :

May 1, 2012

Actual Primary Completion Date :

May 1, 2015

Actual Study Completion Date :

Nov 1, 2015

Arms and Interventions

Arm	Intervention/Treatment
Experimental: 21-Day Regimen 560 mg oral rigosertib in the morning and 280 mg rigosertib in the afternoon on days 1 to 21 of 21-day cycle	Drug: rigosertib Rigosertib sodium will be available as soft gel capsules in strengths of 280 mg and 70 mg. Rigosertib will be administered on an outpatient basis. Patients will take a 560 mg dose (e.g., 2 x 280 mg capsules) of oral rigosertib in the morning and 280 mg dose (e.g., 1 x 280 mg capsules) of oral rigosertib every day of 21-day cycles. Rigosertib should be taken in a fasting state (defined by at least 30 minutes before next meal) BID at 12 hr intervals (with a window of 2 hr). Any vomited dose will be reported as a missed dose. The patient will fill a diary indicating the day and time of drug intake. Other Names: rigosertib sodium ON 01910.Na oral rigosertib

Arm

Intervention/Treatment

Experimental: 21-Day Regimen

560 mg oral rigosertib in the morning and 280 mg rigosertib in the afternoon on days 1 to 21 of 21-day cycle

Drug: rigosertib

Rigosertib sodium will be available as soft gel capsules in strengths of 280 mg and 70 mg. Rigosertib will be administered on an outpatient basis. Patients will take a 560 mg dose (e.g., 2 x 280 mg capsules) of oral rigosertib in the morning and 280 mg dose (e.g., 1 x 280 mg capsules) of oral rigosertib every day of 21-day cycles. Rigosertib should be taken in a fasting state (defined by at least 30 minutes before next meal) BID at 12 hr intervals (with a window of 2 hr). Any vomited dose will be reported as a missed dose. The patient will fill a diary indicating the day and time of drug intake.

Other Names:

rigosertib sodium

ON 01910.Na

oral rigosertib

Outcome Measures

Primary Outcome Measures

Number of units of red blood cell transfusions [8 weeks]
Number of units of red blood cell transfusions will be compared with the pretreatment transfusion number in the previous 8 weeks.

Secondary Outcome Measures

Number of Adverse Events (AEs) [From date of randomization until 30 days after last dose of study drug]
AEs reported by the patient or observed by the Investigator or study site personnel Safety assessments will be counted and documented on Case Report Forms and source documents. All AEs from signature of the ICF through 30 days after a patient discontinues from the study will be included.
Bone marrow blasts [4 weeks]
Change in number of bone marrow blasts will be compared to pretreatment.
Complete blood count [4 weeks]
Complete blood count with differential.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Diagnosis of MDS confirmed by bone marrow aspirate and/or biopsy within 6 weeks prior to first dose of study drug according to World Health Organization (WHO) or French-American-British (FAB) classification
MDS classified as Low risk or Int-1 risk (any cytogenetics) or Trisomy 8 Int-2 risk, according to IPSS classification
Transfusion dependency defined by at least 4 units of RBC administered within 8 weeks before baseline
Off all other treatments for MDS (azacitidine, decitabine, lenalidomide, chemotherapy, immunosuppressive agents) for at least 4 weeks
ECOG performance status of 0, 1 or 2

Exclusion Criteria:

Ongoing clinically significant anemia due to factors such as iron, B12, or folate deficiencies, auto-immune or hereditary hemolysis, or gastrointestinal (GI) bleeding, unless stabilized for 1 week after RBC transfusion
Serum ferritin <50 ng/mL
Hypoplastic MDS (cellularity <10%)
Any active malignancy within the past year, except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix or breast
Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia
Active infection not adequately responding to appropriate therapy
Total bilirubin ≥1.5 mg/dL not related to hemolysis or Gilbert's disease
ALT/AST ≥2.5 x upper limit of normal (ULN)
Serum creatinine ≥2.0 mg/dL
Ascites requiring active medical management including paracentesis
Hyponatremia (defined as serum sodium value of <130 mEq/L)
Female patients who are pregnant or lactating
Patients who are unwilling to follow strict contraception requirements
Female patients with reproductive potential who do not have a negative urine beta-human chorionic gonadotropin (bHCG) pregnancy test at Screening
Major surgery without full recovery or major surgery within 3 weeks of rigosertib treatment start
Uncontrolled hypertension (defined as a systolic pressure ≥160 mmHg and/or a diastolic pressure ≥110 mmHg)
New onset seizures (within 3 months prior to the first dose of rigosertib) or poorly controlled seizures
Any other concurrent investigational agent or chemotherapy, radiotherapy, or immunotherapy
Chronic use (>2 weeks) of corticosteroids (>10 mg/24 hr equivalent prednisone) within 4 weeks of starting rigosertib
Investigational therapy within 4 weeks of starting rigosertib
Psychiatric illness or social situation that would limit the patient's ability to tolerate and/or comply with study requirements

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Mayo Clinic	Scottsdale	Arizona	United States	85259
2	Winship Cancer Institute, Emory University	Atlanta	Georgia	United States	30322
3	Mayo Clinic	Rochester	Minnesota	United States	55905
4	Columbia University Medical Center	New York	New York	United States	10032
5	Bon Secours St. Francis Hospital	Greenville	South Carolina	United States	29601